Naiyer A. Rizvi on Muck Rack

Naiyer A. Rizvi

As seen in: Immuno-Oncology Technology, Nature, The Oncologist, JAMA Oncology, Science Magazine, The New England Journal of Medicine, Healio, HemOnc Today, Journal of Clinical Oncology, OncLive
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Naiyer A.

Contact Naiyer A., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors - Nature

|
By Ferdinandos Skoulidis, Ana Cobo Verified, Meagan Montesion, Yi Yu, Natalie I. Vokes, Joseph Murray, Justin F. Gainor, Catherine Shu, Collin M Blakely, Chad V. Pecot, Fabrizio Tabbò, Matthias Scheffler, Meghan J. Mooradian, Kurt A. Schalper, Valsamo Anagnostou, Patrick M. Forde, Amy Cummings, Jonathan Goldman, Sharyn I. Katz, Ying Ni, Ludovic Lacroix, Yasir Y. Elamin, Marcelo V. Negrao, Vincent Lam, Whitney Lewis, Jack A. Roth, Stephen Swisher, Richard Lee, Teng Zhou, Jianjun Zhang, Lauren A Byers, don gibbons, J. Lee, Trever G. Bivona, Edward B. Garon, Naiyer A. Rizvi, Giorgio Vittorio Scagliotti, Benjamin Besse, Roy S. Herbst, Heather Wakelee, Nathan Pennell, Pasi A. Jänne, David P. Carbone, Charles M. Rudin, Lee A. Albacker, Solange Peters, Melissa Johnson, Kwok Wong, Monte M. Winslow, Tina Cascone
| Nature Verified
Abstract For patients with advanced non-small-cell lung cancer (NSCLC), dual immune checkpoint blockade (ICB) with CTLA4 inhibitors and PD-1 or PD-L1 inhibitors (hereafter, PD-(L)1 inhibitors) is associated with higher rates of anti-tumour activity and immune-related toxicities, when compared with treatment with PD-(L)1 inhibitors alone. However, there are currently no validated biomarkers to identify which patients will benefit from dual ICB1,2.
Open in Who Shared Issue with article?

FDA approves Libtayo for NSCLC subset

|
By Naiyer A. Rizvi
| HemOnc Today Verified
February 22, 2021 2 min read ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The FDA approved cemiplimab-rwlc monotherapy as first-line treatment for certain patients with advanced non-small cell lung cancer.
Open in Who Shared Issue with article?

Management Strategies for Early-Onset Pulmonary Events Associated with Brigatinib

|
By D. Ross Camidge, Naiyer A. Rizvi, Aliyah Pabani, Ronni M. Miller
| jto.org
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Figure 1 Pretreatment scan of early-onset pulmonary event case 1 with pneumonia, pulmonary emboli, and possible radiation pneumonitis taken 2 weeks before commencement of brigatinib therapy.
Open in Who Shared Issue with article?
See all 12 licensed articles (13 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified